Cannabis Report
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: ahab333
Search This Board: 
Last Post: 7/21/2018 1:02:39 PM - Followers: 72 - Board type: Free - Posts Today: 2

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

Cannabis Report
BTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: Statement of Changes in Beneficial Ownership (4) 07/12/2018 07:51:37 PM
BTX News: Statement of Changes in Beneficial Ownership (4) 07/12/2018 07:47:15 PM
BTX News: AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Resea... 07/11/2018 07:00:00 AM
BTX News: BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares 07/10/2018 07:00:00 AM
BTX News: Statement of Changes in Beneficial Ownership (4) 07/03/2018 06:49:01 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1009   Settlement is only 2 days now, so it A Dinosaur 07/21/18 01:02:39 PM
#1008   True Date for AGE Spinoff Shares? bobby2loaves 07/21/18 12:01:39 PM
#1007   I think it appears that shares are starting terry hallinan 07/18/18 12:37:14 PM
#1006   I think it appears that shares are starting ahab333 07/18/18 12:04:56 PM
#1005   this isn't just a pie-in-the-sky idea. terry hallinan 07/13/18 11:06:33 AM
#1004   AgeX merely trying to reinvent modern medicine bobby2loaves 07/13/18 08:59:44 AM
#1003   nsomniyak, Are we sure AgeX will be publicly traded terry hallinan 07/13/18 01:36:49 AM
#1002   Are we sure AgeX will be publicly traded nsomniyak 07/12/18 09:31:21 PM
#1001   West could surely sell snow to Eskimos - terry hallinan 07/11/18 04:07:55 PM
#1000   Thanks, Bobby. Clears up a lot for terry hallinan 07/11/18 09:49:34 AM
#999   I kind of backed into these numbers. bobby2loaves 07/11/18 08:54:09 AM
#998   AgeX Website Revamp bobby2loaves 07/11/18 08:06:51 AM
#997   Nice, Bobby, but how did you come up terry hallinan 07/11/18 08:04:48 AM
#996   The Shell Game bobby2loaves 07/11/18 07:22:30 AM
#995   Thank you but this is just one of terry hallinan 07/10/18 04:11:05 PM
#994   Glad to hear your dog has improved with ahab333 07/10/18 03:27:58 PM
#993   will we be around to benefit from it terry hallinan 07/10/18 02:31:34 PM
#992   Thank you for the response. I have thefamilyman 07/10/18 12:48:50 PM
#991   Your right and I agree on BTX as ahab333 07/10/18 12:03:37 PM
#990   Family, the distribution ratio has not been determined ahab333 07/10/18 12:00:34 PM
#989   Greetings All. I am new to the thefamilyman 07/10/18 11:49:28 AM
#988   I have not been as enthusiastic about the terry hallinan 07/10/18 10:37:50 AM
#987   Finally it's here: Distribution of shares notice. Got ahab333 07/10/18 09:39:02 AM
#986   Wouldn't it be nice if there were another terry hallinan 07/06/18 12:06:27 PM
#985   Yes, it's totally unbelievable what might come to ahab333 07/06/18 11:34:37 AM
#984   Re: Competition for Cardiovascular Regeneration (AGEX-VASC1) bobby2loaves 07/06/18 06:23:53 AM
#983   I wonder if this is the kind of terry hallinan 07/05/18 07:31:14 PM
#982   Competition for Cardiovascular Regeneration (AGEX-VASC1)? bobby2loaves 07/05/18 12:00:20 PM
#981   BioTime Awarded Grant From the NIH terry hallinan 06/29/18 09:44:19 AM
#980   You are interesting Terry with you posts. ahab333 06/27/18 10:48:36 PM
#979   UGH! $2.07. terry hallinan 06/27/18 05:20:47 PM
#978   New Low of the year, UGH! $2.07. ahab333 06/27/18 01:29:06 PM
#977   I still haven't seen any additional information about ahab333 06/25/18 12:41:53 PM
#976   BioTime Licenses GMP Cell Line to Goliver Therapeutics[ terry hallinan 06/25/18 07:35:38 AM
#975   AGEX-iTR1547 On Adis Insight Site bobby2loaves 06/13/18 09:21:11 AM
#974   Article from FightAging.org bobby2loaves 06/13/18 09:16:15 AM
#973   AI And Biotech Companies In The East And bobby2loaves 06/12/18 02:23:24 PM
#971   AgeX sold at $2.50 a share. Cincinnatus 06/11/18 11:29:23 AM
#970   News of 7% stake in Agex from Juvenescence ahab333 06/11/18 11:10:49 AM
#969   Here is AGE's business strategy as stated in bobby2loaves 06/10/18 08:01:23 AM
#967   Nowhere does it say anything about a topical Cincinnatus 06/09/18 03:02:30 PM
#966   The key question here will mainly come from ahab333 06/09/18 11:19:14 AM
#965   Topical application to a heart muscle? How do you DeepDive 06/09/18 02:35:39 AM
#964   More Renelon info... Cincinnatus 06/08/18 03:28:26 PM
#963   Renelon Excerpts from Today Form 10 Filing bobby2loaves 06/08/18 02:17:38 PM
#962   New information. Cincinnatus 06/08/18 12:25:12 PM
#961   Information just came to my email from BTX ahab333 06/08/18 11:23:33 AM
#960   John Mauldin named to AgeX BOD. Patrick Cincinnatus 06/06/18 11:10:43 AM
#959   A lesson my brother taught me when he terry hallinan 06/06/18 07:13:07 AM
#958   I've probably eaten worse. A lesson my brother A Dinosaur 06/05/18 10:09:08 PM
PostSubject